Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,545,482
  • Shares Outstanding, K 58,838
  • Annual Sales, $ 793,740 K
  • Annual Income, $ 313,880 K
  • 60-Month Beta 0.71
  • Price/Sales 7.30
  • Price/Cash Flow 17.11
  • Price/Book 4.65
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 44.57%
  • Historical Volatility 29.47%
  • IV Percentile 8%
  • IV Rank 16.66%
  • IV High 66.13% on 09/13/21
  • IV Low 40.26% on 08/05/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 364

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.75
  • Number of Estimates 9
  • High Estimate -0.60
  • Low Estimate -0.89
  • Prior Year -1.53
  • Growth Rate Est. (year over year) +50.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.04 +1.30%
on 12/03/21
117.86 -20.03%
on 11/10/21
-17.81 (-15.89%)
since 11/03/21
3-Month
93.04 +1.30%
on 12/03/21
117.86 -20.03%
on 11/10/21
-3.56 (-3.64%)
since 09/03/21
52-Week
79.07 +19.19%
on 07/27/21
125.61 -24.97%
on 12/24/20
-6.10 (-6.08%)
since 12/03/20

Most Recent Stories

More News
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a...

RHHBY : 49.3500 (-0.33%)
SRPT : 78.50 (-5.64%)
BPMC : 94.25 (-4.32%)
DCPH : 8.00 (-2.79%)
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

CTIC : 1.6100 (+11.81%)
AMGN : 202.44 (+0.63%)
VRTX : 203.81 (-0.31%)
BPMC : 94.25 (-4.32%)
DCPH : 8.00 (-2.79%)
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

CTIC : 1.6100 (+11.81%)
AMGN : 202.44 (+0.63%)
VRTX : 203.81 (-0.31%)
BPMC : 94.25 (-4.32%)
DCPH : 8.00 (-2.79%)
Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics

Blueprint Medicines (BPMC) inks an agreement to acquire privately held Lengo Therapeutics. The company is looking to boost its lung cancer portfolio with this acquisition.

SRPT : 78.50 (-5.64%)
VTVT : 1.1400 (-7.32%)
BPMC : 94.25 (-4.32%)
EDIT : 27.72 (-7.69%)
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

NVS : 80.00 (+0.06%)
PFE : 54.27 (+2.32%)
BPMC : 94.25 (-4.32%)
DCPH : 8.00 (-2.79%)
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

NVS : 80.00 (+0.06%)
BPMC : 94.25 (-4.32%)
EDIT : 27.72 (-7.69%)
DCPH : 8.00 (-2.79%)
Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU

Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.

RHHBY : 49.3500 (-0.33%)
SRPT : 78.50 (-5.64%)
VKTX : 4.91 (-5.39%)
BPMC : 94.25 (-4.32%)
Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues

Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.

REGN : 635.16 (+0.18%)
RHHBY : 49.3500 (-0.33%)
ALKS : 22.04 (-0.32%)
BPMC : 94.25 (-4.32%)
Blueprint Medicines (BPMC) Reports Q3 Loss, Misses Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -18.34% and -39.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?...

BPMC : 94.25 (-4.32%)
Blueprint Medicines: Q3 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Thursday reported a third-quarter loss of $117.2 million, after reporting a profit in the same period a year earlier.

BPMC : 94.25 (-4.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Key Turning Points

3rd Resistance Point 103.55
2nd Resistance Point 101.20
1st Resistance Point 97.73
Last Price 94.25
1st Support Level 91.91
2nd Support Level 89.56
3rd Support Level 86.09

See More

52-Week High 125.61
Fibonacci 61.8% 107.83
Fibonacci 50% 102.34
Fibonacci 38.2% 96.85
Last Price 94.25
52-Week Low 79.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar